CD44 and cancer: While LMW-HAs do also bind to CD44 and thereby exert important regulatory roles in the TME, as they inhibit CD44 clustering and have an antagonistic effect on HMW-HA activity, LMW-HAs are preferentially recognized by RHAMM [74,75], which is upregulated in disseminating cancer cells and alters the HA signaling of CD44 [74,75].